Skip to main content
SpringerLink
Log in

Expert’s comment concerning Grand Rounds case entitled “Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation” by Deekonda P, Stokes OM, Chan D (Eur Spine J [2016]: DOI 10.1007/s00586-016-4822-8)

  • Expert's Comment
  • Published:
European Spine Journal Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Deekonda P, Stokes OM, Chan D (2016) Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation. Eur Spine J. https://doi.org/10.1007/s00586-016-4822-8

    Article  PubMed  Google Scholar 

  2. European Medicines Agency (2018) Xarelto 2.5 mg, Summary of product characteristics https://www.medicines.org.uk/emc/product/3410/smpc. Accessed 20 Nov 2018

  3. PHARMAC, Best Practice Advocacy Centre New Zealand, New Zealand Government (2017) Guidelines for management of bleeding with dabigatran or rivaroxaban: for possible use in local management protocols. https://bpac.org.nz/2018/docs/dabigatran-rivaroxaban-bleeding-management.pdf. Accessed 20 Nov 2018

  4. Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M (2013) Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 160(1):35–46

    Article  CAS  PubMed  Google Scholar 

  5. Clinical Excellence Commission (2017) Non-vitamin K antagonist oral anticoagulant (NOAC) Guidelines, Updated July 2017. Sydney, Australia

  6. Sarode R, Milling TJ Jr, Refaai MA et al (2013) Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 128:1234–1243

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Levy JH, Moore KT, Neal MD, Schneider D, Marcsisin VS, Ariyawansa J, Weitz JJ (2018) Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. Thromb Haemost 16(1):54–64

    Article  CAS  Google Scholar 

  8. Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R (2011) Clinical review: prothrombin complex concentrates—evaluation of safety and thrombogenicity. Crit Care 15(1):201–209

    Article  PubMed  PubMed Central  Google Scholar 

  9. Connolly SJ, Milling TJ Jr, Eikelboom JW et al (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375(12):1131–1141. https://doi.org/10.1056/NEJMoa1607887

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Radcliff KE, Ong A, Parvizi J, Post Z, Orozco F (2014) Rivaroxaban-induced epidural hematoma and cauda equina syndrome after total knee arthroplasty: a case report. Orthop Surg 2014(6):69–71. https://doi.org/10.1111/os.12085

    Article  Google Scholar 

  11. Zaarour M, Hassan S, Thumallapally N, Dai Q (2015) Rivaroxaban-induced nontraumatic spinal subdural hematoma: an uncommon yet life-threatening complication. Case Rep Hematol. https://doi.org/10.1155/2015/275380

    Article  PubMed  PubMed Central  Google Scholar 

  12. Pollack CV, Reilly PA, Eikelboom J et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520. https://doi.org/10.1056/NEJMoa1502000

    Article  CAS  PubMed  Google Scholar 

  13. The EINSTEIN-PE Investigators (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297. https://doi.org/10.1056/NEJMoa1113572

    Article  Google Scholar 

  14. United States Food and Drug Administration (2016) Xarelto medication guide https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202439s017lbl.pdf. Accessed 18 Nov 2018

  15. Hylek EM, Held C, Alexander JH et al (2014) Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 63(20):2148–2150. https://doi.org/10.1016/j.jacc.2014.02.549

    Article  Google Scholar 

  16. Saxena N, Parajuli S (2016) Spontaneous perinephric haematoma with newer oral anticoagulation in kidney transplant recipient. J Nephrol Renal Ther 2(1):1–2. https://doi.org/10.24966/NRT-7313/100002

    Article  Google Scholar 

  17. Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e326S–e350S. https://doi.org/10.1378/chest.11-2298

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sherwood MW, Douketis JD, Patel MR et al (2014) Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation 129(18):1850–1859

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, The Royal Devon and Exeter Hospital, Barrack Road, Devon, Exeter, EX2 5DW, UK

    Anthony Todd

Authors
  1. Anthony Todd
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony Todd.

Ethics declarations

Conflict of interest

The author declares that he has no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Todd, A. Expert’s comment concerning Grand Rounds case entitled “Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation” by Deekonda P, Stokes OM, Chan D (Eur Spine J [2016]: DOI 10.1007/s00586-016-4822-8). Eur Spine J 28, 693–695 (2019). https://doi.org/10.1007/s00586-018-5843-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00586-018-5843-2

Search

Navigation